This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41375-024-02393-6/MediaObjects/41375_2024_2393_Fig1_HTML.png)
Data availability
Data available on request with email to corresponding author.
References
van Genderen PJ, Michiels JJ. Acquired von Willebrand disease. Baillieres Clin Haematol. 1998;11:319–30.
Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020;105:2032–7.
Brysland SA, Maqbool MG, Talaulikar D, Gardiner EE. Bleeding Propensity in Waldenstrom Macroglobulinemia: Potential Causes and Evaluation. Thromb Haemost. 2022;122:1843–57.
Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575–82.
Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2019;184:1011–4.
Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Lecocq S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood. 2012;120:3214–21.
Treon SP, Tedeschi A, San-Miguel J, Garcia-Sanz R, Anderson KC, Kimby E, et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom’s macroglobulinemia on diagnostic and response criteria. Semin Hematol. 2023;60:97–106.
Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003;29:479–88.
Lopez JA, Dong JF. Shear stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation. Blood Coagul Fibrinolysis. 2005;16:S11–6.
Chohan KL, Kapoor P. BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia. Hemato. 2023;4:135–57.
Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038–50.
Owen RG, McCarthy H, Rule S, D’Sa S, Thomas SK, Tournilhac O, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7:e112–e21.
Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117:6777–85.
Kapoor P, Paludo J, Abeykoon JP. Frontline Management of Waldenstrom Macroglobulinemia with Chemoimmunotherapy. Hematol Oncol Clin North Am. 2023;37:671–87.
Chohan KL, Kapoor P. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenstrom Macroglobulinemia. Curr Hematol Malig Rep. 2024;19:163–74.
Author information
Authors and Affiliations
Contributions
KLC, RKP, MS, JPA designed this study, analyzed/interpreted the data and wrote the manuscript. SZ, JP, RG, AP, AA, JMC, CAT, ACK, SA, TMH, TEW, MAG, DD, FKB, AD, NL, SKK, WN, SMA, PK, interpreted the data and assisted in writing the manuscript. All authors provided final approval of the manuscript and are accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chohan, K.L., Pruthi, R.K., Zanwar, S. et al. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events. Leukemia (2024). https://doi.org/10.1038/s41375-024-02393-6
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41375-024-02393-6